Development and validation of a bioanalytical method for the determination of the cholecystokinin type-1 (CCK(1)) receptor antagonist dexloxiglumide in human plasma.
A sensitive bioanalytical method for the measurement of dexloxiglumide, a new selective and potent cholecystokinin type-1 (CCK(1)) receptor antagonist, in plasma, is reported. The method is based on reversed-phase liquid chromatography with ultraviolet absorption detection. Samples are extracted under acidic conditions into an organic solvent, and following evaporation, reconstitution and centrifugation stages, the supernatant is injected on to an ODS column with detection at 244 nm. The method has been validated over the concentration range 0.2-20 microgram/ml, 0.2 microgram/ml being the lower limit of quantification. The overall precision and accuracy (expressed as relative error) of the method was less than 6.1 and 2.3%, respectively. Dexloxigulmide was shown to be stable in plasma when stored at -20 degrees C for at least 200 days. The method is suitable for studying the pharmacokinetics of dexloxiglumide in man.
Brodie
R
R
Department of Bioanalysis, Huntingdon Life Sciences, Cambridgeshire PE28 4HS, Huntingdon, UK. brodier@ukorg.huntingdon.com
Peard
A
A
Roth
A
A
Persiani
S
S
Makovec
F
F
D'Amato
M
M
D002138:Calibration; D006801:Humans; D010421:Pentanoic Acids / Q000097:blood* / Q000493:pharmacokinetics; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D012015:Reference Standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D010421:Pentanoic Acids; D011949:Receptors, Cholecystokinin; C103490:dexloxiglumide